CDC7 Inhibitor Combination Therapy for Chemoresistant Proliferative Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative diseases, such as cancer, lack effective therapeutic regimens that target the Cdc7-Dbf4 kinase, which is crucial for DNA replication and is often overexpressed in cancers, leading to chemotherapy resistance and aggressive malignancies.
Innovation Solution
A method involving the administration of a pharmaceutical composition combining a compound of Formula (A) or (B) with one or more antineoplastic agents, where the compound inhibits Cdc7 kinase activity, thereby blocking cell cycle progression and inducing apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat cancer, then some cancer cells are killed, but chemotherapy resistance develops leading to treatment failure
Solution Approach 1:
The patent changes the therapeutic parameter by targeting a different molecular pathway (Cdc7 kinase) that is essential for DNA replication in cancer cells. By inhibiting Cdc7 instead of using conventional chemotherapy agents, the treatment bypasses the resistance mechanism that has developed against traditional chemotherapies, thereby restoring treatment effectiveness.
Solution Approach 2:
The patent extracts and targets the specific molecular mechanism (Cdc7-Dbf4 kinase complex) that drives DNA replication in cancer cells. By isolating and inhibiting this specific target with selective inhibitors, the treatment avoids the non-specific toxicity and resistance issues associated with conventional chemotherapy while maintaining anti-cancer efficacy.
2Productivity
If Cdc7 kinase activity is inhibited to block cell cycle progression, then cancer cell proliferation is suppressed, but normal cells may also be affected
Solution Approach 1:
The patent applies local quality by designing Cdc7 inhibitors with selective toxicity toward cancer cells. The inhibitors exploit the overexpression and heightened dependency on Cdc7 kinase in cancer cells compared to normal cells, thereby achieving localized therapeutic effect on the pathological tissue while sparing healthy cells from significant damage.
Solution Approach 2:
The patent utilizes the dynamic difference in Cdc7 kinase dependency between cancer and normal cells. Cancer cells exhibit dynamic overexpression and absolute dependency on Cdc7 for survival, whereas normal cells have lower baseline expression and can compensate through alternative pathways. This dynamic disparity allows selective inhibition of cancer cell proliferation while maintaining normal cell function.
Data Source
AI summary
The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CFC7 inhibitor comprises granaticin B. In an embodiment, the antneoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.